Heterogeneous methodology of racial/ethnic classification may be responsible for the different risk assessments for prostate cancer between Black and White men in Brazil - Abstract

OBJECTIVES: To evaluate if the different results of prostate cancer risk between black and white Brazilian men may be associated with the varying methodology used to define participants as either Blacks or Whites.

PATIENTS AND METHODS: We evaluated median PSA values, rate of PSA level =4.0 ng/mL, indications for prostate biopsy, prostate cancer detection rate, biopsy/cancer rate, cancer/biopsy rate, and the relative risk of cancer between blacks versus whites, blacks versus non-blacks (browns and whites), non-whites (browns and blacks) versus whites, African versus non-African descendants, and African descendants or blacks versus non-African descendants and non-blacks.

RESULTS: From 1544 participants, there were 51.4% whites, 37.2% browns, 11.4% blacks, and 5.4% African descendants. Median PSA level was 0.9 ng/mL in whites, browns, and non-African descendants, compared to 1.2 ng/mL in blacks, and African descendants or blacks, and 1.3 ng/mL in African descendants. Indications for prostate biopsy were present in 16.9% for African descendants, 15.9% of black, 12.3% of white, 11.4% for non-African descendants, and 9.9% of brown participants. Prostate cancer was diagnosed in 30.3% of performed biopsies: 6.2% of African descendants, 5.1% of blacks, 3.3% of whites, 3.0% of non-African descendants, and 2.6% of browns.".

CONCLUSIONS: Median PSA values were higher for Blacks versus Whites in all classification systems, except for non-white versus white men. The rate of prostate biopsy, prostate cancer detection rate, and relative risk for cancer was increased in African descendants, and African descendants or blacks, compared to non-African descendants, and non-African descendants and non-blacks, respectively.

Written by:
Romero FR, Xavier LR, Romero AW, Almeida RM, Matias JE, Tambara R Filho.   Are you the author?
Hospital Policlínica Cascavel, Cascavel, PR, Brazil; Faculdade Assis Gurgacz (FAG), Cascavel, PR, Brazil; Instituto Curitiba de Saúde, Curitiba, PR, Brazil; Hospital de Clínicas da Universidade Federal do Paran á, Curitiba, PR, Brazil.


Reference: Int Braz J Urol. 2015 Mar-Apr;41(2):360-366.
doi: 10.1590/S1677-5538.IBJU.2015.02.25

PubMed Abstract
PMID: 26005980

UroToday.com Prostate Cancer Section